Novel CAR Technology To Transform Cancer Therapy
Chimeric antigen receptor (CAR) therapies involve the use of engineered receptors capable of redirecting immune cells to recognize and destroy cancer cells expressing a specific antigen. Currently, CAR T cells dominate the field of CAR therapy.
However, collecting T cells is costly and time-consuming, CAR T-cell therapies have limited effectiveness in treating solid tumors and CAR T cells struggle to penetrate the tumor microenvironment.
This whitepaper explores the benefits of developing CAR therapies using alternative immune cell types.
Download this whitepaper to learn more about:
- CAR molecule design
- The safety advantages of CAR natural killer cells
- Developments in macrophage-based therapies